The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays

Journal of Immunological Methods

Volumn 259, Issue 1-2, 2002, Pages 95-110

  Britten, Cedrik M ^a   Meyer, Ralf G ^a   Kreer, Tanja ^a   Drexler, Ingo ^b   Wölfel, Thomas ^a   Herr, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

CD8+ T cells; ELISPOT assay; HLA A*0201; K562; Peptides

Indexed keywords

BINDING PROTEIN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PEPTIDE; TUMOR ANTIGEN; VIRUS ANTIGEN; HLA A ANTIGEN; HLA A ANTIGENS;

ACCURACY; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOREACTIVITY; INFLUENZA VIRUS; MELANOMA; MOLECULAR CLONING; MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; CELL STRAIN K 562; GENETICS; IMMUNOLOGY; METHODOLOGY; SENSITIVITY AND SPECIFICITY; STANDARD; T LYMPHOCYTE;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; INFLUENZA VIRUS; INSECTA;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HLA-A ANTIGENS; HUMAN; IMMUNOASSAY; INTERFERON TYPE II; K562 CELLS; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; TRANSFECTION;

EID: 0036006510     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(01)00499-9     Document Type: Article

References (49)

1. PMA-treated K-562 leukemia cells mediate a TH2-specific expansion of CD4+ T cells in vitro
2. Dendritic cells and the control of immunity
3. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2
4. Presentation of viral antigen controlled by a gene in the major histocompatibility complex
5. Reverse ELISPOT assay for clonal analysis of cytokine production: I. Enumeration of gamma-interferon-secreting cells
6. Development of a candidate HLA-A*0201-restricted peptide-based vaccine against human cytomegalovirus infection
7. Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker
8. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo
9. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
10. The biochemistry and cell biology of antigen processing and presentation
11. HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation
12. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens
13. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens
14. + T lymphocytes from human blood
15. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
16. + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
17. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma Elispot assay
18. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
19. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia
20. Rapid effector function in CD8+ memory T cells
21. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2
22. CD28/B7 system of T cell costimulation
23. + T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
24. Costimulation of T-cell growth
25. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
26. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
27. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17
28. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol
29. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes
30. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
31. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
32. Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets
33. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
34. Analysis of the T cell response to tumor and viral peptide antigens by an IFN-gamma-ELISPOT assay
35. Quantitation of antigen-reactive T cells in peripheral blood by IFN-gamma-ELISPOT assay and chromium-release assay: A four-centre comparative trial
36. Roles of adhesion molecules in T-cell recognition: Fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation
37. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
38. HLA class I alleles of LCL721 and 174XCEM.T2 (T2)
39. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
40. Identification of wilde-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay
41. Vaccination with MAGE3/A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
42. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein
43. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: I. Induction of a primary cytotoxic T lymphocyte response in humans
44. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
45. T cell activation pathways: B7, LFA-3, ICAM-1 shape unique T cell profiles
46. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL)
47. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
48. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
49. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope